Raptor Pharmaceutical Corp. to Present at the Oppenheimer 22nd Annual Healthcare Conference
NOVATO, Calif., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive Officer will present an overview of the Company at the Oppenheimer 22nd Annual Healthcare Conference. Raptor's presentation will take place at The Waldorf=Astoria Hotel in New York City on Wednesday, December 14th at 11:25am ET.
A live audio webcast and 14-day archive of the presentation may be accessed via the Investors and Media section of Raptor's website www.raptorpharma.com .
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2") and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com .
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180
CONTACT: Trout Group (investors) Lauren Glaser (646) 378-2972 firstname.lastname@example.org EVC Group (media) Janine McCargo (646) 688-0425 email@example.comRaptor Pharmaceutical Corp. 2011 GlobeNewswire, Inc.